• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

PLoS Biol . Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonh

tetano

Editor, Senior Moderator
PLoS Biol


. 2022 May 5;20(5):e3001609.
doi: 10.1371/journal.pbio.3001609. eCollection 2022 May.
Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates


Daniel Y Zhu[SUP] 1 [/SUP], Matthew J Gorman[SUP] 2 [/SUP], Dansu Yuan[SUP] 2 [/SUP], Jingyou Yu[SUP] 3 [/SUP], Noe B Mercado[SUP] 3 [/SUP], Katherine McMahan[SUP] 3 [/SUP], Erica N Borducchi[SUP] 3 [/SUP], Michelle Lifton[SUP] 3 [/SUP], Jinyan Liu[SUP] 3 [/SUP], Felix Nampanya[SUP] 3 [/SUP], Shivani Patel[SUP] 3 [/SUP], Lauren Peter[SUP] 3 [/SUP], Lisa H Tostanoski[SUP] 3 [/SUP], Laurent Pessaint[SUP] 4 [/SUP], Alex Van Ry[SUP] 4 [/SUP], Brad Finneyfrock[SUP] 4 [/SUP], Jason Velasco[SUP] 4 [/SUP], Elyse Teow[SUP] 4 [/SUP], Renita Brown[SUP] 4 [/SUP], Anthony Cook[SUP] 4 [/SUP], Hanne Andersen[SUP] 4 [/SUP], Mark G Lewis[SUP] 4 [/SUP], Douglas A Lauffenburger[SUP] 1 [/SUP], Dan H Barouch[SUP] 2 3 5 [/SUP], Galit Alter[SUP] 2 [/SUP]



Affiliations

Abstract

Despite the rapid creation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccines, the precise correlates of immunity against severe Coronavirus Disease 2019 (COVID-19) are still unknown. Neutralizing antibodies represent a robust surrogate of protection in early Phase III studies, but vaccines provide protection prior to the evolution of neutralization, vaccines provide protection against variants that evade neutralization, and vaccines continue to provide protection against disease severity in the setting of waning neutralizing titers. Thus, in this study, using an Ad26.CoV2.S dose-down approach in nonhuman primates (NHPs), the role of neutralization, Fc effector function, and T-cell immunity were collectively probed against infection as well as against viral control. While dosing-down minimally impacted neutralizing and binding antibody titers, Fc receptor binding and functional antibody levels were induced in a highly dose-dependent manner. Neutralizing antibody and Fc receptor binding titers, but minimally T cells, were linked to the prevention of transmission. Conversely, Fc receptor binding/function and T cells were linked to antiviral control, with a minimal role for neutralization. These data point to dichotomous roles of neutralization and T-cell function in protection against transmission and disease severity and a continuous role for Fc effector function as a correlate of immunity key to halting and controlling SARS-CoV-2 and emerging variants.
 
Back
Top Bottom